We're currently experiencing extremely high call volumes. We're very sorry for any inconvenience this might cause. If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Bristol Myers Squibb (BMY) Com Stk USD 0.10 (CDI)

Sell:$59.17 Buy:$59.18 Change: $0.92 (1.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$59.17
Buy:$59.18
Change: $0.92 (1.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
Sell:$59.17
Buy:$59.18
Change: $0.92 (1.58%)
Prices delayed by at least 15 minutes | Switch to live prices |
Ex-dividend
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.

Contact details

Address:
430 E 29th St Fl 14
NEW YORK
10016-8367
United States
Telephone:
+1 (212) 5464000
Website:
https://www.bms.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BMY
ISIN:
US1101221083
Market cap:
$131.79 billion
Shares in issue:
2.26 billion
Sector:
Pharmaceuticals
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Giovanni Caforio
    Chairman of the Board, Chief Executive Officer
  • David Elkins
    Executive Vice President and Chief Financial Officer Member of the Leadership Team
  • Ann Judge
    Chief Human Resource Officer, Senior Vice President Member of the Leadership Team
  • Sandra Leung
    Executive Vice President, General Counsel
  • John Elicker
    Executive Vice President of Investor Relations
  • Nadim Ahmed
    Executive Vice President and President - Hematology
  • Christopher Boerner
    Executive Vice President and Chief Commercial Officer
  • Samit Hirawat
    Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team
  • Kathryn Metcalfe
    Executive Vice President - Corporate Affairs Member of the Leadership Team
  • Elizabeth Mily
    Executive Vice President - Strategy & Business Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.